Company News
Telix Shares Up 6.7% After FDA Acceptance
Telix Pharmaceuticals ADR (NASDAQ:TLX) surged 6.7% after FDA accepted its resubmitted NDA for TLX101-Px, a glioma PET imaging agent.
The FDA set a PDUFA goal date of September 11, 2026, and granted Or
